Combination Therapies and New Molecular Targets—Presentations from AACR 2021

Conference Correspondent —June 19, 2021
David R. Spigel, MD
Chief Scientific Officer; Director
Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, TN
Dr David Spigel reviews potentially practice-changing data on EGFR-TKI combination therapies in NSCLC, new approaches to advanced NSCLC and CNS involvement, and hopeful early data with novel targeted agents.
Related Articles
2021 Midyear Review: Non–Small-Cell Lung Cancer
Conference Correspondent
Every year, researchers and clinicians report on exciting advancements in the diagnosis and treatment of cancer. In 2021, despite the COVID-19 pandemic, developments in the management of lung cancer continue to be important and intriguing.
Exciting New Data Presented on NSCLC at AACR 2021
David R. Spigel, MD
Conference Correspondent
Dr David Spigel discusses key presentations on immunotherapy and targeted therapy in the neoadjuvant and adjuvant settings in NSCLC.
Practice-Changing Data in NSCLC from ASCO 2021
Mark A. Socinski, MD
Conference Correspondent
Dr Mark Socinski provides his insights into important new data on EGFR inhibitors and immunotherapy in the first-line setting for NSCLC.
Last modified: June 22, 2021

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State

    Please enter your mailing address.

    Address Line 2
    Zip Code